Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: clochard who wrote (3181)	3/30/1998 10:51:00 AM
From: Dauntless	Read Replies (1) \| Respond to of 7041

Steve "THEY DID NOT" Salgo you wrote to Hank: <<<When Johnson and Johnson withdrew supprt for Amalyn (AMLN), the stock dropped 50% and stayed there, and this is a serious company with a lot of potential. I expect an even worse scenario for ZONA because there is apparantly nothing left to expect for investors. They are just waiting around to have their heads handed to them instead of cutting their losses, being the suckers that they are.>>> This is exactly the type of uninformed comment (should I say "attack") that I referred to that attempts to draw an analogy between the SGP deal with Zonagen & another Big Pharma/Biotech deal that was abandoned. The deal between J&J and Amalyn was struck long before the phase III trials were completed - in fact, there were additional phase III trials scheduled that had not even begun yet. The fact that Zonagen's trials were completed before the deal with SGP makes it that much more LIKELY that SGP will complete the NDA filing & subsequently market the product. Granted, nothing is guaranteed - except your inane posts & personal attacks. BTW, SI now offers spell checking - try it sometime.